Immunotherapy trial aims to help rectal cancer patients avoid surgery
NCT ID NCT06640049
First seen Nov 17, 2025 · Last updated Apr 08, 2026 · Updated 17 times
Summary
This study is testing whether an immunotherapy drug called dostarlimab can effectively treat certain types of rectal cancer without needing surgery or radiation. It involves 23 Chinese participants with untreated, locally advanced rectal cancer who have specific genetic markers in their tumors. The main goal is to see if the treatment leads to a complete disappearance of cancer that lasts for at least 12 months, potentially allowing patients to preserve their rectum.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, RECTAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Chengdu, 610041, China
-
GSK Investigational Site
Chongqing, 400010, China
-
GSK Investigational Site
Guangzhou, 510060, China
-
GSK Investigational Site
Guangzhou, 510655, China
-
GSK Investigational Site
Hangzhou, 310016, China
-
GSK Investigational Site
Hangzhou, China
-
GSK Investigational Site
Jinan, 250117, China
-
GSK Investigational Site
Kunming, 650106, China
-
GSK Investigational Site
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.